STAT

A writer shared her story about getting frightening genetic results online. The response was surprising

A writer shared her story about getting frightening genetic results online. The response was surprising.

This is a lightly edited transcript from a recent episode of STAT’s biotech podcast, “The Readout LOUD.” Like it? Consider subscribing to hear every episode.

Over the past decade, more than 25 million people have ordered at-home DNA testing kits from companies like 23andMe and Ancestry.com. You spit in a tube, send it away, and get notified by email when your results are ready. Initially aimed at providing information about ancestry, some companies now test for certain genetic mutations that are strongly correlated with the risk of developing cancer, Alzheimer’s disease, or other serious conditions.

Dorothy Pomerantz is one of those 25 million people. Last year, almost on a lark, she bought a 23andMe test and sent her spit to Silicon Valley. But what she learned went far beyond the for STAT’s First Opinion, and spoke with STAT about the reaction to it.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks